| 101121-2 | Candida albicans and tropicalis DNA (Blood, qualitative, naa with probe detection) | MICRO |
| 101122-0 | Mephobarbital (Blood, confirmatory method) | DRUG/TOX |
| 101123-8 | Bacterial carbapenem resistance blaIMI gene (qualitative, molecular method) | ABXBACT |
| 101124-6 | Bacterial carbapenem resistance blaIMI+blaNMC genes (qualitative, molecular method) | ABXBACT |
| 101125-3 | Bacterial carbapenem resistance blaOXA-235-like gene (qualitative, molecular method) | ABXBACT |
| 101126-1 | Bacterial carbapenem resistance blaOXA-24+blaOXA-40 gene (qualitative, molecular method) | ABXBACT |
| 101127-9 | Bacterial carbapenem resistance blaSIM gene (qualitative, molecular method) | ABXBACT |
| 101128-7 | Theoretical limit of detection in Specimen (calculation) | MISC |
| 101129-5 | Laboratory device Assay Sensitivity | DEVICES |
| 10113-9 | ST wave end displacement in lead V2 | EKG.MEAS |
| 101130-3 | Mast cells/cells (Bone Marrow, flow cytometry (fc)) | HEM/BC |
| 101131-1 | B-cell precursors (Bone Marrow, flow cytometry (fc)) | HEM/BC |
| 101132-9 | Glucose post XXX challenge panel - Serum or Plasma | PANEL.CHAL |
| 101133-7 | Organ AndOr tissue donation consent Document | DOC.ONTOLOGY |
| 101134-5 | Appointment reminder | DOC.ONTOLOGY |
| 101135-2 | Ambulance Discharge summary | DOC.ONTOLOGY |
| 101136-0 | Radiation oncology End of treatment letter | DOC.ONTOLOGY |
| 101137-8 | MNS29 (qualitative) | BLDBK |
| 101138-6 | ER^a Ab (qualitative) | BLDBK |
| 101139-4 | Hro Ab (qualitative) | BLDBK |
| 10114-7 | ST wave end displacement in lead V3 | EKG.MEAS |
| 101140-2 | Salmonella sp Ag (Stool, qualitative, rapid immunoassay) | MICRO |
| 101141-0 | NAT2 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) | MOLPATH.PHARMG |
| 101142-8 | NAT2 gene allele or Tissue (Blood, molecular genetics method nominal) | MOLPATH.PHARMG |
| 101143-6 | NAT2 gene product metabolic activity interpretation or Tissue Qualitative (Blood, qualitative, molecular genetics method) | MOLPATH.PHARMG |
| 101144-4 | Ustekinumab and Ustekinumab Ab panel - Serum or Plasma | PANEL.DRUG/TOX |
| 101145-1 | Ustekinumab (immunoassay --trough) | DRUG/TOX |
| 101146-9 | Monocyte subsets panel - Blood (flow cytometry (fc)) | PANEL.CELLMARK |
| 101147-7 | Monocytes/Leukocytes (Blood, flow cytometry (fc)) | CELLMARK |
| 101148-5 | CD14+CD16- (Classical) Monocytes/Monocytes (Blood) | CELLMARK |
| 101149-3 | Borrelia burgdorferi IgM Ab index and CSF | MICRO |
| 10115-4 | ST wave end displacement in lead V4 | EKG.MEAS |
| 101150-1 | Right ventricular Cardiac output (fick method) | HEMODYN.MOLEC |
| 101151-9 | Right ventricular Cardiac output (indicator dilution) | HEMODYN.MOLEC |
| 101152-7 | Mitochondria whole genome analysis or Tissue (Blood, molecular genetics method) | MOLPATH |
| 101153-5 | Chemokine (C-C motif) ligand 14 (Urine, immunoassay) | CHEM |
| 101154-3 | Calprotectin | CHEM |
| 101155-0 | Alpha hydroxyetizolam/Creatinine (Urine, confirmatory method) | DRUG/TOX |
| 101156-8 | Alpha hydroxyetizolam (Urine, qualitative, confirmatory method) | DRUG/TOX |
| 101157-6 | Flualprazolam/Creatinine (Urine, confirmatory method) | DRUG/TOX |
| 101158-4 | Flualprazolam (Urine, qualitative, confirmatory method) | DRUG/TOX |
| 101159-2 | Flubromazolam/Creatinine (Urine, confirmatory method) | DRUG/TOX |
| 10116-2 | ST wave end displacement in lead V5 | EKG.MEAS |
| 101160-0 | Flubromazolam (Urine, qualitative, confirmatory method) | DRUG/TOX |
| 101161-8 | p-Fluorofentanyl/Creatinine (Urine, confirmatory method) | DRUG/TOX |
| 101162-6 | p-Fluorofentanyl (Urine, qualitative, confirmatory method) | DRUG/TOX |
| 101163-4 | Brorphine (Urine, confirmatory method) | DRUG/TOX |
| 101164-2 | Brorphine/Creatinine (Urine, confirmatory method) | DRUG/TOX |
| 101165-9 | Brorphine (Urine, qualitative, confirmatory method) | DRUG/TOX |
| 101166-7 | Metonitazene (Urine, confirmatory method) | DRUG/TOX |